ID   DNMT1_HUMAN             Reviewed;        1616 AA.
AC   P26358; A0AV63; B7ZLW6; Q9UHG5; Q9ULA2; Q9UMZ6;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2001, sequence version 2.
DT   10-MAY-2017, entry version 196.
DE   RecName: Full=DNA (cytosine-5)-methyltransferase 1;
DE            Short=Dnmt1;
DE            EC=2.1.1.37;
DE   AltName: Full=CXXC-type zinc finger protein 9;
DE   AltName: Full=DNA methyltransferase HsaI;
DE            Short=DNA MTase HsaI;
DE            Short=M.HsaI;
DE   AltName: Full=MCMT;
GN   Name=DNMT1; Synonyms=AIM, CXXC9, DNMT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1594447; DOI=10.1093/nar/20.9.2287;
RA   Yen R.-W.C., Vertino P.M., Nelkin B.D., Yu J.J., Deiry W.E.,
RA   Cumaraswamy A., Lennon G.G., Trask B.J., Celano P., Baylin S.B.;
RT   "Isolation and characterization of the cDNA encoding human DNA
RT   methyltransferase.";
RL   Nucleic Acids Res. 20:2287-2291(1992).
RN   [2]
RP   SEQUENCE REVISION TO N-TERMINUS.
RX   PubMed=8940105; DOI=10.1074/jbc.271.49.31092;
RA   Yoder J.A., Yen R.-W.C., Vertino P.M., Bestor T.H., Baylin S.B.;
RT   "New 5' regions of the murine and human genes for DNA (cytosine-5)-
RT   methyltransferase.";
RL   J. Biol. Chem. 271:31092-31097(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Prostatic carcinoma;
RA   Li L.C., Au H., Chui R., Dahiya R.;
RT   "Human DNA methyltransferase (DNMT1) is alternatively spliced.";
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2).
RX   PubMed=10449766; DOI=10.1073/pnas.96.17.9751;
RA   Hsu D.-W., Lin M.-J., Lee T.-L., Wen S.-C., Chen X., Shen C.-K.J.;
RT   "Two major forms of DNA (cytosine-5) methyltransferase in human
RT   somatic tissues.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:9751-9756(1999).
RN   [7]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2).
RX   PubMed=10753866; DOI=10.1074/jbc.275.15.10754;
RA   Bonfils C., Beaulieu N., Chan E., Cotton-Montpetit J., MacLeod A.R.;
RT   "Characterization of the human DNA methyltransferase splice variant
RT   Dnmt1b.";
RL   J. Biol. Chem. 275:10754-10760(2000).
RN   [8]
RP   INTERACTION WITH PCNA, AND MUTAGENESIS.
RX   PubMed=9302295; DOI=10.1126/science.277.5334.1996;
RA   Chuang L.S.-H., Ian H.-I., Koh T.-W., Ng H.-H., Xu G., Li B.F.L.;
RT   "Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for
RT   p21WAF1.";
RL   Science 277:1996-2000(1997).
RN   [9]
RP   INTERACTION WITH MBD2 AND MBD3.
RX   PubMed=10947852; DOI=10.1046/j.1365-2443.2000.00359.x;
RA   Tatematsu K., Yamazaki T., Ishikawa F.;
RT   "MBD2-MBD3 complex binds to hemi-methylated DNA and forms a complex
RT   containing DNMT1 at the replication foci in late S phase.";
RL   Genes Cells 5:677-688(2000).
RN   [10]
RP   INTERACTION WITH HDAC2 AND DMAP1.
RX   PubMed=10888872; DOI=10.1038/77023;
RA   Rountree M.R., Bachman K.E., Baylin S.B.;
RT   "DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at
RT   replication foci.";
RL   Nat. Genet. 25:269-277(2000).
RN   [11]
RP   INTERACTION WITH RB1; E2F1 AND HDAC1.
RX   PubMed=10888886; DOI=10.1038/77124;
RA   Robertson K.D., Ait-Si-Ali S., Yokochi T., Wade P.A., Jones P.L.,
RA   Wolffe A.P.;
RT   "DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses
RT   transcription from E2F-responsive promoters.";
RL   Nat. Genet. 25:338-342(2000).
RN   [12]
RP   TISSUE SPECIFICITY.
RX   PubMed=10325416; DOI=10.1093/nar/27.11.2291;
RA   Robertson K.D., Uzvolgyi E., Liang G., Talmadge C., Sumegi J.,
RA   Gonzales F.A., Jones P.A.;
RT   "The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate
RT   mRNA expression in normal tissues and overexpression in tumors.";
RL   Nucleic Acids Res. 27:2291-2298(1999).
RN   [13]
RP   INTERACTION WITH DNMT3A AND DNMT3B, AND SUBCELLULAR LOCATION.
RX   PubMed=12145218; DOI=10.1093/emboj/cdf401;
RA   Kim G.-D., Ni J., Kelesoglu N., Roberts R.J., Pradhan S.;
RT   "Co-operation and communication between the human maintenance and de
RT   novo DNA (cytosine-5) methyltransferases.";
RL   EMBO J. 21:4183-4195(2002).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-127 AND SER-714, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH EED AND EZH2.
RX   PubMed=16357870; DOI=10.1038/nature04431;
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RT   "The Polycomb group protein EZH2 directly controls DNA methylation.";
RL   Nature 439:871-874(2006).
RN   [16]
RP   ERRATUM.
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RL   Nature 446:824-824(2006).
RN   [17]
RP   DE NOVO DNA METHYLATION OF TARGET GENES.
RX   PubMed=17200670; DOI=10.1038/ng1950;
RA   Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M.,
RA   Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E.,
RA   Bergman Y., Simon I., Cedar H.;
RT   "Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes
RT   for de novo methylation in cancer.";
RL   Nat. Genet. 39:232-236(2007).
RN   [18]
RP   FUNCTION, AND MUTAGENESIS OF CYS-653; CYS-656; CYS-659; CYS-664;
RP   CYS-667 AND CYS-670.
RX   PubMed=18754681; DOI=10.1021/bi8011725;
RA   Pradhan M., Esteve P.-O., Chin H.G., Samaranayke M., Kim G.-D.,
RA   Pradhan S.;
RT   "CXXC domain of human DNMT1 is essential for enzymatic activity.";
RL   Biochemistry 47:10000-10009(2008).
RN   [19]
RP   FUNCTION.
RX   PubMed=18413740; DOI=10.1158/0008-5472.CAN-07-6654;
RA   Sun L., Huang L., Nguyen P., Bisht K.S., Bar-Sela G., Ho A.S.,
RA   Bradbury C.M., Yu W., Cui H., Lee S., Trepel J.B., Feinberg A.P.,
RA   Gius D.;
RT   "DNA methyltransferase 1 and 3B activate BAG-1 expression via
RT   recruitment of CTCFL/BORIS and modulation of promoter histone
RT   methylation.";
RL   Cancer Res. 68:2726-2735(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-732, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [21]
RP   METHYLATION AT LYS-70, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18438403; DOI=10.1038/nchembio.88;
RA   Rathert P., Dhayalan A., Murakami M., Zhang X., Tamas R.,
RA   Jurkowska R., Komatsu Y., Shinkai Y., Cheng X., Jeltsch A.;
RT   "Protein lysine methyltransferase G9a acts on non-histone targets.";
RL   Nat. Chem. Biol. 4:344-346(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-127; SER-143; SER-152;
RP   SER-154 AND SER-394, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [24]
RP   SUMOYLATION, INTERACTION WITH UBC9, AND MUTAGENESIS OF CYS-1226.
RX   PubMed=19450230; DOI=10.1042/BJ20090142;
RA   Lee B., Muller M.T.;
RT   "SUMOylation enhances DNA methyltransferase 1 activity.";
RL   Biochem. J. 421:449-461(2009).
RN   [25]
RP   HOMODIMERIZATION.
RX   PubMed=19173286; DOI=10.1002/jcb.22071;
RA   Fellinger K., Rothbauer U., Felle M., Laengst G., Leonhardt H.;
RT   "Dimerization of DNA methyltransferase 1 is mediated by its regulatory
RT   domain.";
RL   J. Cell. Biochem. 106:521-528(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-127, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-173; LYS-1111; LYS-1113 AND
RP   LYS-1115, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-394 AND SER-714, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   PHOSPHORYLATION AT SER-154.
RX   PubMed=21565170; DOI=10.1016/j.bbrc.2011.04.115;
RA   Lavoie G., St-Pierre Y.;
RT   "Phosphorylation of human DNMT1: implication of cyclin-dependent
RT   kinases.";
RL   Biochem. Biophys. Res. Commun. 409:187-192(2011).
RN   [31]
RP   ACETYLATION AT LYS-160; LYS-188; LYS-259; LYS-366; LYS-749; LYS-891;
RP   LYS-957; LYS-961; LYS-975; LYS-1054; LYS-1111; LYS-1113; LYS-1115;
RP   LYS-1117; LYS-1349 AND LYS-1415, AND DEACETYLATION BY SIRT1.
RX   PubMed=21947282; DOI=10.1128/MCB.06147-11;
RA   Peng L., Yuan Z., Ling H., Fukasawa K., Robertson K., Olashaw N.,
RA   Koomen J., Chen J., Lane W.S., Seto E.;
RT   "SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and
RT   alters its activities.";
RL   Mol. Cell. Biol. 31:4720-4734(2011).
RN   [32]
RP   METHYLATION AT LYS-142, AND PHOSPHORYLATION AT SER-143.
RX   PubMed=21151116; DOI=10.1038/nsmb.1939;
RA   Esteve P.O., Chang Y., Samaranayake M., Upadhyay A.K., Horton J.R.,
RA   Feehery G.R., Cheng X., Pradhan S.;
RT   "A methylation and phosphorylation switch between an adjacent lysine
RT   and serine determines human DNMT1 stability.";
RL   Nat. Struct. Mol. Biol. 18:42-48(2011).
RN   [33]
RP   INTERACTION WITH USP7 AND UHRF1.
RX   PubMed=21745816; DOI=10.1093/nar/gkr528;
RA   Felle M., Joppien S., Nemeth A., Diermeier S., Thalhammer V.,
RA   Dobner T., Kremmer E., Kappler R., Langst G.;
RT   "The USP7/Dnmt1 complex stimulates the DNA methylation activity of
RT   Dnmt1 and regulates the stability of UHRF1.";
RL   Nucleic Acids Res. 39:8355-8365(2011).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-127; SER-133 AND
RP   SER-714, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-127; THR-137; SER-143;
RP   SER-154; THR-166; SER-312; SER-394; SER-398; SER-549; SER-714 AND
RP   SER-878, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [36]
RP   FUNCTION, POSSIBLE IDENTIFICATION IN A COREPRESSOR COMPLEX, AND
RP   CHROMATIN-BINDING.
RX   PubMed=24623306; DOI=10.7554/eLife.02313;
RA   Serra R.W., Fang M., Park S.M., Hutchinson L., Green M.R.;
RT   "A KRAS-directed transcriptional silencing pathway that mediates the
RT   CpG island methylator phenotype.";
RL   Elife 3:E02313-E02313(2014).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [38]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1609, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.31 ANGSTROMS) OF 351-600 IN COMPLEX WITH ZINC
RP   IONS.
RX   PubMed=21389349; DOI=10.1074/jbc.M110.209882;
RA   Syeda F., Fagan R.L., Wean M., Avvakumov G.V., Walker J.R., Xue S.,
RA   Dhe-Paganon S., Brenner C.;
RT   "The replication focus targeting sequence (RFTS) domain is a DNA-
RT   competitive inhibitor of Dnmt1.";
RL   J. Biol. Chem. 286:15344-15351(2011).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (3.6 ANGSTROMS) OF 646-1600 IN COMPLEX WITH SAH
RP   AND DNA, AND AUTOINHIBITORY LINKER.
RX   PubMed=21163962; DOI=10.1126/science.1195380;
RA   Song J., Rechkoblit O., Bestor T.H., Patel D.J.;
RT   "Structure of DNMT1-DNA complex reveals a role for autoinhibition in
RT   maintenance DNA methylation.";
RL   Science 331:1036-1040(2011).
RN   [41]
RP   VARIANTS HSN1E 490-GLU-TYR-491 AND CYS-495, AND CHARACTERIZATION OF
RP   VARIANTS HSN1E 490-GLU-TYR-491 AND CYS-495.
RX   PubMed=21532572; DOI=10.1038/ng.830;
RA   Klein C.J., Botuyan M.V., Wu Y., Ward C.J., Nicholson G.A.,
RA   Hammans S., Hojo K., Yamanishi H., Karpf A.R., Wallace D.C., Simon M.,
RA   Lander C., Boardman L.A., Cunningham J.M., Smith G.E., Litchy W.J.,
RA   Boes B., Atkinson E.J., Middha S., Dyck P.J.B., Parisi J.E., Mer G.,
RA   Smith D.I., Dyck P.J.;
RT   "Mutations in DNMT1 cause hereditary sensory neuropathy with dementia
RT   and hearing loss.";
RL   Nat. Genet. 43:595-600(2011).
RN   [42]
RP   VARIANTS ADCADN VAL-554; ALA-589 AND PHE-590.
RX   PubMed=22328086; DOI=10.1093/hmg/dds035;
RA   Winkelmann J., Lin L., Schormair B., Kornum B.R., Faraco J.,
RA   Plazzi G., Melberg A., Cornelio F., Urban A.E., Pizza F., Poli F.,
RA   Grubert F., Wieland T., Graf E., Hallmayer J., Strom T.M., Mignot E.;
RT   "Mutations in DNMT1 cause autosomal dominant cerebellar ataxia,
RT   deafness and narcolepsy.";
RL   Hum. Mol. Genet. 21:2205-2210(2012).
CC   -!- FUNCTION: Methylates CpG residues. Preferentially methylates
CC       hemimethylated DNA. Associates with DNA replication sites in S
CC       phase maintaining the methylation pattern in the newly synthesized
CC       strand, that is essential for epigenetic inheritance. Associates
CC       with chromatin during G2 and M phases to maintain DNA methylation
CC       independently of replication. It is responsible for maintaining
CC       methylation patterns established in development. DNA methylation
CC       is coordinated with methylation of histones. Mediates
CC       transcriptional repression by direct binding to HDAC2. In
CC       association with DNMT3B and via the recruitment of CTCFL/BORIS,
CC       involved in activation of BAG1 gene expression by modulating
CC       dimethylation of promoter histone H3 at H3K4 and H3K9. Probably
CC       forms a corepressor complex required for activated KRAS-mediated
CC       promoter hypermethylation and transcriptional silencing of tumor
CC       suppressor genes (TSGs) or other tumor-related genes in colorectal
CC       cancer (CRC) cells (PubMed:24623306). Also required to maintain a
CC       transcriptionally repressive state of genes in undifferentiated
CC       embryonic stem cells (ESCs) (PubMed:24623306). Associates at
CC       promoter regions of tumor suppressor genes (TSGs) leading to their
CC       gene silencing (PubMed:24623306). Promotes tumor growth
CC       (PubMed:24623306). {ECO:0000269|PubMed:16357870,
CC       ECO:0000269|PubMed:18413740, ECO:0000269|PubMed:18754681,
CC       ECO:0000269|PubMed:24623306}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + DNA = S-adenosyl-L-
CC       homocysteine + DNA containing 5-methylcytosine.
CC       {ECO:0000255|PROSITE-ProRule:PRU10018}.
CC   -!- SUBUNIT: Homodimer (PubMed:19173286). Forms a stable complex with
CC       E2F1, BB1 and HDAC1 (PubMed:10888886). Forms a complex with DMAP1
CC       and HDAC2, with direct interaction (PubMed:10888872). Interacts
CC       with the PRC2/EED-EZH2 complex (PubMed:16357870). Probably part of
CC       a corepressor complex containing ZNF304, TRIM28, SETDB1 and DNMT1
CC       (PubMed:24623306). Interacts with UHRF1; promoting its recruitment
CC       to hemimethylated DNA (PubMed:21745816). Interacts with USP7,
CC       promoting its deubiquitination (PubMed:21745816). Interacts with
CC       PCNA (PubMed:9302295). Interacts with MBD2 and MBD3
CC       (PubMed:10947852). Interacts with DNMT3A and DNMT3B
CC       (PubMed:12145218). Interacts with UBC9 (PubMed:19450230).
CC       Interacts with CSNK1D (By similarity). Interacts with HDAC1 (By
CC       similarity). Interacts with BAZ2A/TIP5 (By similarity).
CC       {ECO:0000250|UniProtKB:P13864, ECO:0000269|PubMed:10888872,
CC       ECO:0000269|PubMed:10888886, ECO:0000269|PubMed:10947852,
CC       ECO:0000269|PubMed:12145218, ECO:0000269|PubMed:16357870,
CC       ECO:0000269|PubMed:19173286, ECO:0000269|PubMed:19450230,
CC       ECO:0000269|PubMed:21745816, ECO:0000269|PubMed:24623306,
CC       ECO:0000269|PubMed:9302295}.
CC   -!- INTERACTION:
CC       O75530:EED; NbExp=3; IntAct=EBI-719459, EBI-923794;
CC       Q15910:EZH2; NbExp=8; IntAct=EBI-719459, EBI-530054;
CC       P48552:NRIP1; NbExp=3; IntAct=EBI-719459, EBI-746484;
CC       P09874:PARP1; NbExp=6; IntAct=EBI-719459, EBI-355676;
CC       Q96EB6:SIRT1; NbExp=11; IntAct=EBI-719459, EBI-1802965;
CC       Q96T88:UHRF1; NbExp=12; IntAct=EBI-719459, EBI-1548946;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12145218}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P26358-1; Sequence=Displayed;
CC       Name=2; Synonyms=Dnmt1b;
CC         IsoId=P26358-2; Sequence=VSP_005618;
CC       Name=3;
CC         IsoId=P26358-3; Sequence=VSP_005617;
CC   -!- TISSUE SPECIFICITY: Ubiquitous; highly expressed in fetal tissues,
CC       heart, kidney, placenta, peripheral blood mononuclear cells, and
CC       expressed at lower levels in spleen, lung, brain, small intestine,
CC       colon, liver, and skeletal muscle. Isoform 2 is less expressed
CC       than isoform 1. {ECO:0000269|PubMed:10325416}.
CC   -!- INDUCTION: Its abundance is reduced to non detectable levels at
CC       the G0 phase of the cell cycle and is dramatically induced upon
CC       entrance into the S-phase of the cell cycle.
CC   -!- DOMAIN: The N-terminal part is required for homodimerization and
CC       acts as a regulatory domain.
CC   -!- DOMAIN: The CXXC-type zinc finger specifically binds to
CC       unmethylated CpG dinucleotides, positioning the autoinhibitory
CC       linker between the DNA and the active site, thus providing a
CC       mechanism to ensure that only hemimethylated CpG dinucleotides
CC       undergo methylation. {ECO:0000269|PubMed:21163962}.
CC   -!- PTM: Sumoylated; sumoylation increases activity.
CC       {ECO:0000269|PubMed:19450230}.
CC   -!- PTM: Acetylation on multiple lysines, mainly by KAT2B/PCAF,
CC       regulates cell cycle G(2)/M transition. Deacetylation of Lys-1349
CC       and Lys-1415 by SIRT1 increases methyltransferase activity.
CC       {ECO:0000269|PubMed:21947282}.
CC   -!- PTM: Phosphorylation of Ser-154 by CDKs is important for enzymatic
CC       activity and protein stability. Phosphorylation of Ser-143 by AKT1
CC       prevents methylation by SETD7 therebye increasing DNMT1 stability.
CC       {ECO:0000269|PubMed:21151116, ECO:0000269|PubMed:21565170}.
CC   -!- PTM: Methylation at Lys-142 by SETD7 promotes DNMT1 proteasomal
CC       degradation. {ECO:0000269|PubMed:18438403,
CC       ECO:0000269|PubMed:21151116}.
CC   -!- PTM: Ubiquitinated by UHRF1; interaction with USP7 counteracts
CC       ubiquitination by UHRF1 by promoting deubiquitination and
CC       preventing degradation by the proteasome. {ECO:0000250}.
CC   -!- DISEASE: Neuropathy, hereditary sensory, 1E (HSN1E) [MIM:614116]:
CC       A neurodegenerative disorder characterized by adult onset of
CC       progressive peripheral sensory loss associated with progressive
CC       hearing impairment and early-onset dementia.
CC       {ECO:0000269|PubMed:21532572}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Cerebellar ataxia, deafness, and narcolepsy, autosomal
CC       dominant (ADCADN) [MIM:604121]: An autosomal dominant neurologic
CC       disorder characterized by adult onset of progressive cerebellar
CC       ataxia, narcolepsy, cataplexy, sensorineural deafness, and
CC       dementia. More variable features include optic atrophy, sensory
CC       neuropathy, psychosis, and depression.
CC       {ECO:0000269|PubMed:22328086}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding
CC       methyltransferase superfamily. C5-methyltransferase family.
CC       {ECO:0000255|PROSITE-ProRule:PRU01016}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD54507.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/DNMT1ID40347ch19p13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X63692; CAA45219.1; -; mRNA.
DR   EMBL; AF180682; AAF23609.1; -; mRNA.
DR   EMBL; AC010077; AAD54507.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC011511; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC020931; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC126227; AAI26228.1; -; mRNA.
DR   EMBL; BC144093; AAI44094.1; -; mRNA.
DR   EMBL; AH008119; AAD51619.1; -; Genomic_DNA.
DR   CCDS; CCDS12228.1; -. [P26358-1]
DR   CCDS; CCDS45958.1; -. [P26358-2]
DR   PIR; S22610; S22610.
DR   RefSeq; NP_001124295.1; NM_001130823.2. [P26358-2]
DR   RefSeq; NP_001305659.1; NM_001318730.1.
DR   RefSeq; NP_001305660.1; NM_001318731.1.
DR   RefSeq; NP_001370.1; NM_001379.3. [P26358-1]
DR   UniGene; Hs.202672; -.
DR   PDB; 3EPZ; X-ray; 2.31 A; A/B=351-600.
DR   PDB; 3PTA; X-ray; 3.60 A; A=646-1600.
DR   PDB; 3SWR; X-ray; 2.49 A; A=601-1600.
DR   PDB; 4WXX; X-ray; 2.62 A; A/B=351-1600.
DR   PDB; 4YOC; X-ray; 2.92 A; A=600-1600.
DR   PDB; 4Z96; X-ray; 2.85 A; C=1098-1129.
DR   PDB; 4Z97; X-ray; 3.00 A; C=1098-1129.
DR   PDBsum; 3EPZ; -.
DR   PDBsum; 3PTA; -.
DR   PDBsum; 3SWR; -.
DR   PDBsum; 4WXX; -.
DR   PDBsum; 4YOC; -.
DR   PDBsum; 4Z96; -.
DR   PDBsum; 4Z97; -.
DR   ProteinModelPortal; P26358; -.
DR   SMR; P26358; -.
DR   BioGrid; 108123; 90.
DR   DIP; DIP-39693N; -.
DR   IntAct; P26358; 29.
DR   MINT; MINT-232346; -.
DR   STRING; 9606.ENSP00000352516; -.
DR   BindingDB; P26358; -.
DR   ChEMBL; CHEMBL1993; -.
DR   DrugBank; DB00928; Azacitidine.
DR   DrugBank; DB01262; Decitabine.
DR   DrugBank; DB01099; Flucytosine.
DR   DrugBank; DB01035; Procainamide.
DR   GuidetoPHARMACOLOGY; 2605; -.
DR   REBASE; 1161; M.HsaDnmt1A.
DR   iPTMnet; P26358; -.
DR   PhosphoSitePlus; P26358; -.
DR   BioMuta; DNMT1; -.
DR   DMDM; 12231019; -.
DR   EPD; P26358; -.
DR   MaxQB; P26358; -.
DR   PaxDb; P26358; -.
DR   PeptideAtlas; P26358; -.
DR   PRIDE; P26358; -.
DR   Ensembl; ENST00000340748; ENSP00000345739; ENSG00000130816. [P26358-1]
DR   Ensembl; ENST00000359526; ENSP00000352516; ENSG00000130816. [P26358-2]
DR   Ensembl; ENST00000540357; ENSP00000440457; ENSG00000130816. [P26358-3]
DR   GeneID; 1786; -.
DR   KEGG; hsa:1786; -.
DR   UCSC; uc002mng.4; human. [P26358-1]
DR   CTD; 1786; -.
DR   DisGeNET; 1786; -.
DR   GeneCards; DNMT1; -.
DR   GeneReviews; DNMT1; -.
DR   HGNC; HGNC:2976; DNMT1.
DR   HPA; CAB005876; -.
DR   HPA; HPA002694; -.
DR   MalaCards; DNMT1; -.
DR   MIM; 126375; gene.
DR   MIM; 604121; phenotype.
DR   MIM; 614116; phenotype.
DR   neXtProt; NX_P26358; -.
DR   OpenTargets; ENSG00000130816; -.
DR   Orphanet; 314404; Autosomal dominant cerebellar ataxia, deafness and narcolepsy.
DR   PharmGKB; PA27443; -.
DR   eggNOG; ENOG410IF68; Eukaryota.
DR   eggNOG; COG0270; LUCA.
DR   GeneTree; ENSGT00390000005100; -.
DR   HOGENOM; HOG000082497; -.
DR   HOVERGEN; HBG051384; -.
DR   InParanoid; P26358; -.
DR   KO; K00558; -.
DR   OrthoDB; EOG091G02YU; -.
DR   PhylomeDB; P26358; -.
DR   TreeFam; TF328926; -.
DR   BRENDA; 2.1.1.37; 2681.
DR   Reactome; R-HSA-212300; PRC2 methylates histones and DNA.
DR   Reactome; R-HSA-427413; NoRC negatively regulates rRNA expression.
DR   Reactome; R-HSA-5334118; DNA methylation.
DR   SIGNOR; P26358; -.
DR   ChiTaRS; DNMT1; human.
DR   EvolutionaryTrace; P26358; -.
DR   GeneWiki; DNMT1; -.
DR   GenomeRNAi; 1786; -.
DR   PRO; PR:P26358; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000130816; -.
DR   CleanEx; HS_DNMT1; -.
DR   ExpressionAtlas; P26358; baseline and differential.
DR   Genevisible; P26358; HS.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005721; C:pericentric heterochromatin; IEA:Ensembl.
DR   GO; GO:0005657; C:replication fork; IEA:Ensembl.
DR   GO; GO:0003886; F:DNA (cytosine-5-)-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0009008; F:DNA-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0008327; F:methyl-CpG binding; IEA:Ensembl.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IEA:Ensembl.
DR   GO; GO:0008270; F:zinc ion binding; IEA:Ensembl.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl.
DR   GO; GO:0016569; P:covalent chromatin modification; IEA:UniProtKB-KW.
DR   GO; GO:0006306; P:DNA methylation; TAS:ProtInc.
DR   GO; GO:0043045; P:DNA methylation involved in embryo development; IEA:Ensembl.
DR   GO; GO:0016458; P:gene silencing; IEA:Ensembl.
DR   GO; GO:0010216; P:maintenance of DNA methylation; IDA:UniProtKB.
DR   GO; GO:0045814; P:negative regulation of gene expression, epigenetic; TAS:Reactome.
DR   GO; GO:0051573; P:negative regulation of histone H3-K9 methylation; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0051571; P:positive regulation of histone H3-K4 methylation; IMP:UniProtKB.
DR   GO; GO:0090309; P:positive regulation of methylation-dependent chromatin silencing; IMP:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; IMP:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR001025; BAH_dom.
DR   InterPro; IPR018117; C5_DNA_meth_AS.
DR   InterPro; IPR001525; C5_MeTfrase.
DR   InterPro; IPR031303; C5_meth_CS.
DR   InterPro; IPR022702; Cytosine_MeTrfase1_RFD.
DR   InterPro; IPR010506; DMAP1-bd.
DR   InterPro; IPR017198; DNMT1_meta.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   InterPro; IPR002857; Znf_CXXC.
DR   Pfam; PF01426; BAH; 2.
DR   Pfam; PF06464; DMAP_binding; 1.
DR   Pfam; PF00145; DNA_methylase; 1.
DR   Pfam; PF12047; DNMT1-RFD; 1.
DR   Pfam; PF02008; zf-CXXC; 1.
DR   PIRSF; PIRSF037404; DNMT1; 1.
DR   PRINTS; PR00105; C5METTRFRASE.
DR   SMART; SM00439; BAH; 2.
DR   SMART; SM01137; DMAP_binding; 1.
DR   SUPFAM; SSF53335; SSF53335; 2.
DR   PROSITE; PS51038; BAH; 2.
DR   PROSITE; PS00094; C5_MTASE_1; 1.
DR   PROSITE; PS00095; C5_MTASE_2; 1.
DR   PROSITE; PS51679; SAM_MT_C5; 1.
DR   PROSITE; PS51058; ZF_CXXC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Chromatin regulator; Complete proteome; Deafness; Disease mutation;
KW   DNA-binding; Isopeptide bond; Metal-binding; Methylation;
KW   Methyltransferase; Neuropathy; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Repressor; S-adenosyl-L-methionine;
KW   Transcription; Transcription regulation; Transferase; Ubl conjugation;
KW   Zinc; Zinc-finger.
FT   CHAIN         1   1616       DNA (cytosine-5)-methyltransferase 1.
FT                                /FTId=PRO_0000088034.
FT   DOMAIN       18    103       DMAP-interaction.
FT   DOMAIN      755    880       BAH 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00370}.
FT   DOMAIN      972   1100       BAH 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00370}.
FT   REPEAT     1109   1110       1.
FT   REPEAT     1111   1112       2.
FT   REPEAT     1113   1114       3.
FT   REPEAT     1115   1116       4.
FT   REPEAT     1117   1118       5.
FT   REPEAT     1119   1120       6; approximate.
FT   DOMAIN     1139   1599       SAM-dependent MTase C5-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01016}.
FT   ZN_FING     646    692       CXXC-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00509}.
FT   REGION        1    336       Interaction with the PRC2/EED-EZH2
FT                                complex. {ECO:0000250}.
FT   REGION        1    148       Interaction with DNMT3A.
FT                                {ECO:0000269|PubMed:12145218}.
FT   REGION        1    120       Interaction with DMAP1.
FT                                {ECO:0000269|PubMed:10888872}.
FT   REGION      149    217       Interaction with DNMT3B.
FT                                {ECO:0000269|PubMed:12145218}.
FT   REGION      163    174       Interaction with PCNA.
FT                                {ECO:0000269|PubMed:9302295}.
FT   REGION      308    606       Interaction with the PRC2/EED-EZH2
FT                                complex. {ECO:0000250}.
FT   REGION      310    502       Homodimerization.
FT   REGION      331    550       DNA replication foci-targeting sequence.
FT                                {ECO:0000250}.
FT   REGION      651    697       Required for activity.
FT   REGION      693    754       Autoinhibitory linker.
FT   REGION     1109   1120       6 X 2 AA tandem repeats of K-G.
FT   REGION     1121   1616       Interaction with the PRC2/EED-EZH2
FT                                complex. {ECO:0000250}.
FT   REGION     1139   1616       Catalytic.
FT   REGION     1150   1151       S-adenosyl-L-homocysteine binding.
FT                                {ECO:0000250|UniProtKB:P13864}.
FT   REGION     1168   1169       S-adenosyl-L-homocysteine binding.
FT                                {ECO:0000244|PDB:3PTA,
FT                                ECO:0000269|PubMed:21163962}.
FT   REGION     1190   1191       S-adenosyl-L-homocysteine binding.
FT                                {ECO:0000250|UniProtKB:P13864}.
FT   MOTIF       177    205       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   ACT_SITE   1226   1226
FT   METAL       353    353       Zinc.
FT   METAL       356    356       Zinc.
FT   METAL       414    414       Zinc.
FT   METAL       418    418       Zinc.
FT   BINDING    1146   1146       S-adenosyl-L-homocysteine; via carbonyl
FT                                oxygen. {ECO:0000250|UniProtKB:P13864}.
FT   BINDING    1191   1191       S-adenosyl-L-homocysteine.
FT                                {ECO:0000244|PDB:3PTA,
FT                                ECO:0000269|PubMed:21163962}.
FT   BINDING    1578   1578       S-adenosyl-L-homocysteine; via carbonyl
FT                                oxygen. {ECO:0000244|PDB:3PTA,
FT                                ECO:0000269|PubMed:21163962}.
FT   BINDING    1580   1580       S-adenosyl-L-homocysteine; via amide
FT                                nitrogen. {ECO:0000250|UniProtKB:P13864}.
FT   SITE        509    509       Important for activity. {ECO:0000250}.
FT   MOD_RES      70     70       N6,N6-dimethyllysine.
FT                                {ECO:0000269|PubMed:18438403}.
FT   MOD_RES     127    127       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     133    133       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     137    137       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     141    141       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P13864}.
FT   MOD_RES     142    142       N6-methyllysine; by SETD7.
FT                                {ECO:0000269|PubMed:21151116}.
FT   MOD_RES     143    143       Phosphoserine; by PKB/AKT1.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:21151116}.
FT   MOD_RES     152    152       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     154    154       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:21565170}.
FT   MOD_RES     160    160       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21947282}.
FT   MOD_RES     166    166       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     173    173       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     188    188       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21947282}.
FT   MOD_RES     259    259       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21947282}.
FT   MOD_RES     312    312       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     366    366       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21947282}.
FT   MOD_RES     394    394       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     398    398       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     509    509       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P13864}.
FT   MOD_RES     549    549       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     714    714       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     732    732       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336}.
FT   MOD_RES     749    749       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21947282}.
FT   MOD_RES     878    878       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     891    891       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21947282}.
FT   MOD_RES     957    957       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21947282}.
FT   MOD_RES     961    961       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21947282}.
FT   MOD_RES     975    975       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21947282}.
FT   MOD_RES    1054   1054       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21947282}.
FT   MOD_RES    1111   1111       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861,
FT                                ECO:0000269|PubMed:21947282}.
FT   MOD_RES    1113   1113       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861,
FT                                ECO:0000269|PubMed:21947282}.
FT   MOD_RES    1115   1115       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861,
FT                                ECO:0000269|PubMed:21947282}.
FT   MOD_RES    1117   1117       N6-acetyllysine; by EHMT2.
FT                                {ECO:0000269|PubMed:21947282}.
FT   MOD_RES    1119   1119       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P13864}.
FT   MOD_RES    1121   1121       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P13864}.
FT   MOD_RES    1349   1349       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21947282}.
FT   MOD_RES    1415   1415       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21947282}.
FT   CROSSLNK   1609   1609       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25772364}.
FT   VAR_SEQ       1    336       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_005617.
FT   VAR_SEQ     149    149       P -> RSRDPPASASQVTGIRA (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_005618.
FT   VARIANT      97     97       H -> R (in dbSNP:rs16999593).
FT                                /FTId=VAR_024605.
FT   VARIANT     311    311       I -> V (in dbSNP:rs2228612).
FT                                /FTId=VAR_051960.
FT   VARIANT     490    491       DP -> EY (in HSN1E; unstable protein with
FT                                decreased enzymatic activity and impaired
FT                                heterochromatin binding ability after the
FT                                S phase; dbSNP:rs199473691).
FT                                /FTId=VAR_065965.
FT   VARIANT     495    495       Y -> C (in HSN1E; unstable protein with
FT                                decreased enzymatic activity and impaired
FT                                heterochromatin binding ability after the
FT                                S phase; dbSNP:rs199473690).
FT                                {ECO:0000269|PubMed:21532572}.
FT                                /FTId=VAR_065966.
FT   VARIANT     554    554       A -> V (in ADCADN; dbSNP:rs397509392).
FT                                {ECO:0000269|PubMed:22328086}.
FT                                /FTId=VAR_070055.
FT   VARIANT     589    589       G -> A (in ADCADN; dbSNP:rs397509393).
FT                                {ECO:0000269|PubMed:22328086}.
FT                                /FTId=VAR_070056.
FT   VARIANT     590    590       V -> F (in ADCADN; dbSNP:rs397509391).
FT                                {ECO:0000269|PubMed:22328086}.
FT                                /FTId=VAR_070057.
FT   MUTAGEN     163    163       R->A: Abolishes interaction with PCNA.
FT                                {ECO:0000269|PubMed:9302295}.
FT   MUTAGEN     164    164       Q->A: Abolishes interaction with PCNA.
FT                                {ECO:0000269|PubMed:9302295}.
FT   MUTAGEN     166    166       T->A: Abolishes interaction with PCNA.
FT                                {ECO:0000269|PubMed:9302295}.
FT   MUTAGEN     167    167       I->A: Abolishes interaction with PCNA.
FT                                {ECO:0000269|PubMed:9302295}.
FT   MUTAGEN     169    169       S->A: No loss of interaction with PCNA.
FT                                {ECO:0000269|PubMed:9302295}.
FT   MUTAGEN     170    170       H->V: Abolishes interaction with PCNA.
FT                                {ECO:0000269|PubMed:9302295}.
FT   MUTAGEN     171    171       F->V: Abolishes interaction with PCNA.
FT                                {ECO:0000269|PubMed:9302295}.
FT   MUTAGEN     172    172       A->S: No loss of interaction with PCNA.
FT                                {ECO:0000269|PubMed:9302295}.
FT   MUTAGEN     173    173       K->A: No loss of interaction with PCNA.
FT                                {ECO:0000269|PubMed:9302295}.
FT   MUTAGEN     653    653       C->G: Reduces activity about 10-fold;
FT                                when associated with G-656; G-659; G-664;
FT                                G-667 and G-670.
FT                                {ECO:0000269|PubMed:18754681}.
FT   MUTAGEN     656    656       C->G: Reduces activity about 10-fold;
FT                                when associated with G-653; G-659; G-664;
FT                                G-667 and G-670.
FT                                {ECO:0000269|PubMed:18754681}.
FT   MUTAGEN     659    659       C->G: Reduces activity about 10-fold;
FT                                when associated with G-653; G-656; G-664;
FT                                G-667 and G-670.
FT                                {ECO:0000269|PubMed:18754681}.
FT   MUTAGEN     664    664       C->F: Reduces activity about 10-fold;
FT                                when associated with G-653; G-656; G-659;
FT                                G-667 and G-670.
FT                                {ECO:0000269|PubMed:18754681}.
FT   MUTAGEN     667    667       C->G: Reduces activity about 10-fold;
FT                                when associated with G-653; G-656; G-659;
FT                                G-664 and G-670.
FT                                {ECO:0000269|PubMed:18754681}.
FT   MUTAGEN     670    670       C->G: Reduces activity about 10-fold;
FT                                when associated with G-653; G-656; G-659;
FT                                G-664 and G-667.
FT                                {ECO:0000269|PubMed:18754681}.
FT   MUTAGEN    1226   1226       C->A: Loss of activity.
FT                                {ECO:0000269|PubMed:19450230}.
FT   TURN        354    356       {ECO:0000244|PDB:3EPZ}.
FT   STRAND      359    364       {ECO:0000244|PDB:4WXX}.
FT   HELIX       377    389       {ECO:0000244|PDB:3EPZ}.
FT   STRAND      405    413       {ECO:0000244|PDB:3EPZ}.
FT   STRAND      422    425       {ECO:0000244|PDB:3EPZ}.
FT   TURN        426    430       {ECO:0000244|PDB:3EPZ}.
FT   STRAND      434    441       {ECO:0000244|PDB:3EPZ}.
FT   STRAND      453    458       {ECO:0000244|PDB:3EPZ}.
FT   STRAND      462    467       {ECO:0000244|PDB:3EPZ}.
FT   STRAND      476    480       {ECO:0000244|PDB:3EPZ}.
FT   STRAND      485    488       {ECO:0000244|PDB:3EPZ}.
FT   TURN        493    495       {ECO:0000244|PDB:3EPZ}.
FT   HELIX       496    499       {ECO:0000244|PDB:3EPZ}.
FT   HELIX       504    518       {ECO:0000244|PDB:3EPZ}.
FT   HELIX       524    533       {ECO:0000244|PDB:3EPZ}.
FT   HELIX       538    540       {ECO:0000244|PDB:3EPZ}.
FT   HELIX       547    551       {ECO:0000244|PDB:3EPZ}.
FT   HELIX       554    567       {ECO:0000244|PDB:3EPZ}.
FT   HELIX       575    577       {ECO:0000244|PDB:3EPZ}.
FT   HELIX       579    587       {ECO:0000244|PDB:3EPZ}.
FT   HELIX       592    598       {ECO:0000244|PDB:3EPZ}.
FT   HELIX       622    629       {ECO:0000244|PDB:3SWR}.
FT   TURN        657    659       {ECO:0000244|PDB:3SWR}.
FT   HELIX       670    672       {ECO:0000244|PDB:3SWR}.
FT   TURN        674    677       {ECO:0000244|PDB:4WXX}.
FT   HELIX       687    689       {ECO:0000244|PDB:3SWR}.
FT   HELIX       692    703       {ECO:0000244|PDB:4WXX}.
FT   STRAND      731    735       {ECO:0000244|PDB:3SWR}.
FT   STRAND      738    740       {ECO:0000244|PDB:4WXX}.
FT   STRAND      744    746       {ECO:0000244|PDB:3SWR}.
FT   STRAND      748    752       {ECO:0000244|PDB:3SWR}.
FT   STRAND      755    758       {ECO:0000244|PDB:3SWR}.
FT   STRAND      762    765       {ECO:0000244|PDB:3SWR}.
FT   STRAND      767    769       {ECO:0000244|PDB:3SWR}.
FT   STRAND      775    785       {ECO:0000244|PDB:3SWR}.
FT   TURN        786    788       {ECO:0000244|PDB:3SWR}.
FT   STRAND      789    799       {ECO:0000244|PDB:3SWR}.
FT   HELIX       800    802       {ECO:0000244|PDB:3SWR}.
FT   STRAND      803    805       {ECO:0000244|PDB:4YOC}.
FT   HELIX       806    808       {ECO:0000244|PDB:3SWR}.
FT   STRAND      813    824       {ECO:0000244|PDB:3SWR}.
FT   HELIX       825    827       {ECO:0000244|PDB:3SWR}.
FT   STRAND      828    832       {ECO:0000244|PDB:3SWR}.
FT   STRAND      834    836       {ECO:0000244|PDB:3SWR}.
FT   HELIX       843    845       {ECO:0000244|PDB:3SWR}.
FT   TURN        851    853       {ECO:0000244|PDB:4WXX}.
FT   HELIX       856    860       {ECO:0000244|PDB:3SWR}.
FT   STRAND      862    870       {ECO:0000244|PDB:3SWR}.
FT   TURN        871    874       {ECO:0000244|PDB:3SWR}.
FT   STRAND      875    877       {ECO:0000244|PDB:3SWR}.
FT   STRAND      886    888       {ECO:0000244|PDB:4YOC}.
FT   TURN        889    891       {ECO:0000244|PDB:3SWR}.
FT   HELIX       894    905       {ECO:0000244|PDB:3SWR}.
FT   STRAND      912    916       {ECO:0000244|PDB:3SWR}.
FT   STRAND      921    928       {ECO:0000244|PDB:3SWR}.
FT   STRAND      931    934       {ECO:0000244|PDB:3SWR}.
FT   STRAND      938    941       {ECO:0000244|PDB:3SWR}.
FT   TURN        966    968       {ECO:0000244|PDB:3SWR}.
FT   HELIX       973    975       {ECO:0000244|PDB:3SWR}.
FT   HELIX       976    980       {ECO:0000244|PDB:3SWR}.
FT   STRAND      992   1001       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1005   1008       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1015   1020       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1024   1026       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1031   1034       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1035   1037       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1041   1044       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1048   1052       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1053   1055       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1058   1064       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1065   1067       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1072   1077       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1079   1090       {ECO:0000244|PDB:3SWR}.
FT   TURN       1091   1094       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1095   1097       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1101   1103       {ECO:0000244|PDB:4WXX}.
FT   STRAND     1139   1145       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1150   1158       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1160   1167       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1171   1180       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1184   1187       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1191   1200       {ECO:0000244|PDB:3SWR}.
FT   TURN       1214   1216       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1218   1222       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1231   1233       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1237   1243       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1247   1258       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1261   1268       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1269   1272       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1275   1277       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1278   1289       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1293   1300       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1301   1304       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1311   1318       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1336   1338       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1343   1345       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1348   1350       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1367   1371       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1384   1386       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1395   1401       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1419   1426       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1436   1438       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1451   1453       {ECO:0000244|PDB:3SWR}.
FT   TURN       1462   1464       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1474   1476       {ECO:0000244|PDB:4YOC}.
FT   HELIX      1477   1479       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1480   1482       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1487   1489       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1493   1496       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1499   1503       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1504   1506       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1508   1510       {ECO:0000244|PDB:3SWR}.
FT   TURN       1511   1514       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1523   1525       {ECO:0000244|PDB:3SWR}.
FT   STRAND     1534   1536       {ECO:0000244|PDB:4WXX}.
FT   STRAND     1542   1547       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1550   1556       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1569   1578       {ECO:0000244|PDB:3SWR}.
FT   HELIX      1582   1598       {ECO:0000244|PDB:3SWR}.
SQ   SEQUENCE   1616 AA;  183165 MW;  1E833192D22AFA5B CRC64;
     MPARTAPARV PTLAVPAISL PDDVRRRLKD LERDSLTEKE CVKEKLNLLH EFLQTEIKNQ
     LCDLETKLRK EELSEEGYLA KVKSLLNKDL SLENGAHAYN REVNGRLENG NQARSEARRV
     GMADANSPPK PLSKPRTPRR SKSDGEAKPE PSPSPRITRK STRQTTITSH FAKGPAKRKP
     QEESERAKSD ESIKEEDKDQ DEKRRRVTSR ERVARPLPAE EPERAKSGTR TEKEEERDEK
     EEKRLRSQTK EPTPKQKLKE EPDREARAGV QADEDEDGDE KDEKKHRSQP KDLAAKRRPE
     EKEPEKVNPQ ISDEKDEDEK EEKRRKTTPK EPTEKKMARA KTVMNSKTHP PKCIQCGQYL
     DDPDLKYGQH PPDAVDEPQM LTNEKLSIFD ANESGFESYE ALPQHKLTCF SVYCKHGHLC
     PIDTGLIEKN IELFFSGSAK PIYDDDPSLE GGVNGKNLGP INEWWITGFD GGEKALIGFS
     TSFAEYILMD PSPEYAPIFG LMQEKIYISK IVVEFLQSNS DSTYEDLINK IETTVPPSGL
     NLNRFTEDSL LRHAQFVVEQ VESYDEAGDS DEQPIFLTPC MRDLIKLAGV TLGQRRAQAR
     RQTIRHSTRE KDRGPTKATT TKLVYQIFDT FFAEQIEKDD REDKENAFKR RRCGVCEVCQ
     QPECGKCKAC KDMVKFGGSG RSKQACQERR CPNMAMKEAD DDEEVDDNIP EMPSPKKMHQ
     GKKKKQNKNR ISWVGEAVKT DGKKSYYKKV CIDAETLEVG DCVSVIPDDS SKPLYLARVT
     ALWEDSSNGQ MFHAHWFCAG TDTVLGATSD PLELFLVDEC EDMQLSYIHS KVKVIYKAPS
     ENWAMEGGMD PESLLEGDDG KTYFYQLWYD QDYARFESPP KTQPTEDNKF KFCVSCARLA
     EMRQKEIPRV LEQLEDLDSR VLYYSATKNG ILYRVGDGVY LPPEAFTFNI KLSSPVKRPR
     KEPVDEDLYP EHYRKYSDYI KGSNLDAPEP YRIGRIKEIF CPKKSNGRPN ETDIKIRVNK
     FYRPENTHKS TPASYHADIN LLYWSDEEAV VDFKAVQGRC TVEYGEDLPE CVQVYSMGGP
     NRFYFLEAYN AKSKSFEDPP NHARSPGNKG KGKGKGKGKP KSQACEPSEP EIEIKLPKLR
     TLDVFSGCGG LSEGFHQAGI SDTLWAIEMW DPAAQAFRLN NPGSTVFTED CNILLKLVMA
     GETTNSRGQR LPQKGDVEML CGGPPCQGFS GMNRFNSRTY SKFKNSLVVS FLSYCDYYRP
     RFFLLENVRN FVSFKRSMVL KLTLRCLVRM GYQCTFGVLQ AGQYGVAQTR RRAIILAAAP
     GEKLPLFPEP LHVFAPRACQ LSVVVDDKKF VSNITRLSSG PFRTITVRDT MSDLPEVRNG
     ASALEISYNG EPQSWFQRQL RGAQYQPILR DHICKDMSAL VAARMRHIPL APGSDWRDLP
     NIEVRLSDGT MARKLRYTHH DRKNGRSSSG ALRGVCSCVE AGKACDPAAR QFNTLIPWCL
     PHTGNRHNHW AGLYGRLEWD GFFSTTVTNP EPMGKQGRVL HPEQHRVVSV RECARSQGFP
     DTYRLFGNIL DKHRQVGNAV PPPLAKAIGL EIKLCMLAKA RESASAKIKE EEAAKD
//
